Gyre Therapeutics Inc (GYRE)

Gyre Therapeutics' stock price has been impacted by several events over the past six months, including Q3 2025 results showing revenue of $30.6 million and net income of $5.9 million, positive Phase 3 results for Hydronidone, Q2 2025 financial results with revenue of $26.8 million and net income of $1.6 million, a leadership change with Ping Zhang appointed interim CEO, a $23 million public offering, removal from the Russell indexes, and a recent stock decline with a sell signal issued.

There is no specific data indicating demand seasonality for Gyre Therapeutics' products and services, as demand is generally driven by medical need and regulatory approvals rather than seasonal fluctuations.

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis, with a strategy to develop and commercialize drugs first in China and then replicate this process in the United States. Its major products include ETUARY (pirfenidone capsules) for idiopathic pulmonary fibrosis, Hydronidone (F351) targeting liver fibrosis, Etorel (nintedanib ethanesulfonate soft capsules) for systemic sclerosis-associated and progressive fibrosing interstitial lung disease, Contiva (avatrombopag maleate tablets) for thrombocytopenia, and other pipeline candidates like F573, F528, and F230.

Gyre Therapeutics is headquartered in San Diego, California, USA, and has a significant operational and market presence in the People's Republic of China through Gyre Pharmaceuticals, focusing on developing and commercializing its drug pipeline initially in China before potentially expanding to the United States.

Gyre Therapeutics' brand reputation has been influenced by positive advancements in Hydronidone and strategic acquisitions, but negatively affected by stock underperformance compared to the US Biotechs industry and the broader US Market, as well as an increase in short interest. The company has received a consensus rating of "Hold" from some brokerages, while other analyses indicate a "Strong Buy" consensus from two analysts.

Gyre Therapeutics has 105 institutional owners and shareholders holding 3,713,877 shares, with major institutional owners including Vanguard Group Inc and BlackRock, Inc. GNI Group Ltd. holds a 70% stake, indicating substantial control by public companies, while insiders hold 10.00% of the stock, and institutions hold 23.99%.